No Data
US Stock MarketDetailed Quotes
ANVS Annovis Bio
Watchlist
10.680
+0.380+3.69% Close 12/06 16:00 ET
10.950+0.270+2.53%
Post 17:00 ET
11.220High10.480Low340.51KVolume
10.620Open10.300Pre Close3.67MTurnover4.61%Turnover RatioLossP/E (TTM)109.60MMarket Cap23.88852wk HighLossP/E (Static)10.26MShares5.42052wk Low16.46P/B78.96MFloat Cap132.000Historical High--Dividend TTM7.39MShs Float2.418Historical Low--Div YieldTTM7.18%Amplitude10.780Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Annovis Bio Company
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
News
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in
Buy Rating Affirmed for Annovis Bio Amidst Strong Clinical Trial Progress and Robust Financial Position
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio with a Buy and maintains $30 price target.
Comments
Watching for data in Q1, make a note!
$Annovis Bio(ANVS.US$ Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease
Andrew Walsh's appointment, with his solid financial operations experience, is a key move in Annovis Bio's growth strategy. His skills are expected to be crucial for the firm's future success, particularly as it prepares for essential clinical trial data in 2024.
Update
$Annovis Bio(ANVS.US$ Annovis Bio (NYSE:ANVS) said the Data and Safety Monitoring Board has issued a positive recommendation for its Phase 2/3 study of its drug buntanetap in the treatment of mild-to-moderate Alzheimer’s disease.
Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
The company started the study in late March 2023.
Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
The company started the study in late March 2023.
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--